PaxMedica (NASDAQ: PXMD) Hoping to Boost Patient Independence with Potential ASD Treatment – InvestorBrandNetwork (IBN) Content Platform

PaxMedica is developing PAX-101, which utilizes the company’s proprietary source of suramin sodium, for the treatment of ASD (Autism Spectrum Disorder)
There is no FDA-approved treatment for the core symptoms of autism, even though the rates of autism spectrum disorder have jumped significantly from 2000 to 2020
ASD is characterized by deficits in social communication, restricted and repetitive patterns of behavior, and significant impairment in functioning, three core aspects of the disease that PaxMedica aims to address
The company announced positive topline results from a Phase 2 study evaluating PAX-101 as a potential treatment for ASD and hopes to replicate these results in a larger trial, for which PaxMedica is preparing

In the U.S., the rates of autism spectrum disorder (“ASD”), a diverse group of early-onset and lifelong neurodevelopmental conditions, have more than quadrupled from 2000 to 2020, according to data published by the Centers for Disease Control and Prevention (“CDC”) (https://ibn.fm/fRYhj). Researchers attribute the increase to advances in diagnostic capabilities as well as greater understanding and awareness of ASD (https://ibn.fm/v6gtI). PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company intent on developing novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions.

Estimates from the CDC’s Autism and Development Disabilities Monitoring (“ADDM”) Network, which pools data from multiple sites across the United States, showed that about 1 in 36 children had been identified with ASD in 2020, up from 1 in 150 in 2000. Correspondingly, the combined prevalence per…